EBS up +6.49% percent right now. $EBS High is at 24.46 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 3:59 AM

EBS up +6.49% percent right now. $EBS High is at 24.46 and the Low 23.32 with current volume of 558,700.

Recent News posted below.

EBS Emergent Biosolutions Recent Headline News

Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 23.95 (+1.46)

Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 23.95 (+1.46)

Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included:
EBS: 23.95 (+1.46)

3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 23.95 (+1.46), NLNK: 32.15 (-2.54), TEVA: 57.70 (-1.02), AMRI: 16.84 (+0.75)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), SNY: 45.69 (-0.17), FOLD: 5.72 (-0.16)

Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), EXAS: 22.82 (-0.52), AFFX: 9.43 (-0.02)

Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), EXAS: 22.82 (-0.52)

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Mon Oct 20, 6:08AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 23.95 (+1.46)

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), RARE: 44.71 (-0.15), LGND: 53.94 (-0.97)

Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Infinity Pharmaceuticals (INFI) announced disappointing results from a phase IIa study on duvelisib.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), INFI: 13.01 (+0.87), ABBV: 61.50 (-1.21)

Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:30PM CDT
Health Canada issued a notice of compliance to Gilead's (GILD) Harvoni.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)

What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), ENZ: 4.94 (-0.13), EPZM: 23.75 (+0.19)

Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:30PM CDT
Alexion (ALXN) has filed a new drug application for asfotase alfa in Japan.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), LGND: 53.94 (-0.97)

Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), AGIO: 72.06 (-11.03), CELG: 106.45 (-0.69)

GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:48PM CDT
GW Pharmaceuticals (GWPH) announced disappointing results from a phase IIa study on GWP42003.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GWPH: 73.97 (-0.41), LGND: 53.94 (-0.97)

Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), NVAX: 4.95 (-0.20)

Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 3:30PM CDT
Alnylam Pharmaceuticals (ALNY) announced several study results on its pipeline candidates.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)

Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:45PM CDT
Alnylam (ALNY) revealed encouraging initial results from an ongoing phase II study on patisiran.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)

Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), PLX: 2.04 (-0.01), EPZM: 23.75 (+0.19)

Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), FCSC: 2.73 (+0.06), EPZM: 23.75 (+0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RideNow Gears Up for Earnings Amidst Industry Shifts

Highway to Earnings: RideNow's Third Quarter Call Alright, folks, this is the moment the powersports crowd has been itching for. RideNow Group, Inc. (NASDAQ: RDNW) is set to roll out their third-quarter financial results on November 10, 2026. If you're in for a wild ride—pun fully intended—mark this on your calendars. With this company hogging the spotlight in the...

Cogent's VR-1.1: Revolutionizing Cybersecurity Benchmarking

VR-1.1 Makes Waves in Cybersecurity Who would've thought the cyber scene was ripe for a shake-up? Well, Cogent Security's VR-1.1 is here to prove that notion dead right. Their latest AI powerhouse has topped the charts, outperforming existing tools like Claude Code and Codex on LiveCVEBench. VR-1.1 clocked in with a 57.9% success rate in patching vulnerabilities in real...

XPLR Infrastructure Posts Solid Q3 Results, Eyes Growth

Third Quarter Results: Crunching the Numbers Every season brings new tidbits, and when XPLR Infrastructure, LP (NYSE: XIFR) dropped their third-quarter 2026 results, you bet I was ready with my magnifying glass. November 3rd was the day to circle on your calendars, as the folks over at Juno Beach sure had something to say. They’ve plastered the details across their...

DRC's Grand Inga Project Sparks American Interest

Transformative Power: Enter the Grand Inga The winds of change are gusting over the Congo River, with the United States and Democratic Republic of the Congo (DRC) soldiering forward on the Grand Inga hydropower complex. Friends, this isn't just another investment; it's an audacious move aimed at flipping the DRC's power dynamics upside down. Both nations are knee-deep in...

Life with PAH: A Journey of Awareness and Hope

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Instanodes Tackling Quantum Threats in Blockchain

Diving Into Quantum Cryptography for Blockchain Instanodes is throwing down the gauntlet for the blockchain crowd as the field of quantum computing edges ever closer to unsettling the cryptographic order. This company's latest play? Post-quantum account engineering for major players like Ethereum and Solana. And it's not just tinkering—they're giving the status quo a...

SlidesAI Launches Standalone Platform for Presentations

From Add-on to Standalone: SlidesAI's Big Leap You know what they say: time waits for no one, and that seems true in tech too. Those suit-and-tie presentation days? SlidesAI just took a swing at redefining them. Once a trusty sidekick locked into Google Slides, it's now captaining its own ship. Welcome to the SlidesAI standalone presentation platform—where AI meets your...

Jon Gregoire Leads Parkview's Next Growth Phase

Steering Parkview into New Waters Every now and then, a company gets a leader who feels like a tailor-made fit for its ambitions. Parkview Dental Partners just scored big with Jon Gregoire taking the helm as CEO. Gregoire, a seasoned DSO bigwig with a knack for M&A, is set to power up the gears for Parkview’s next growth spurt. We're talking about a guy who knows the...

Staypineapple Backs Vets: A Heartwarming Initiative

When Hotels Stand Up for Heroes Every now and then, you stumble upon a company doing something genuinely good, and Staypineapple's effort this November is one of those rare gems. In honor of Veterans Day, they're opening their checkbook to sling some real support to our nation’s vets and retired first responders. Their chosen cause? The American Humane Society's...

GreenCore's Agentic Shopping Hub: Disrupting FMCG Market

GreenCore's Bold Move in FMCG Retail Just when you thought retail couldn't get any more futuristic, here comes GreenCore Solutions Corp. (GSC) shaking up the game with their Agentic Shopping Hub. For the uninitiated, we're not just talking about another e-commerce gimmick—this is a cultural shift. FMCG brands are being told to 'bring their agent' into a realm where AI...